Evaluation of Safety and Efficacy of Morpheus8 Applicator for the Treatment of Focal Hyperhidrosis of the Axillae Using Radio Frequency

Inclusion Criteria: Subject is 18 years of age or older at the time of consent. * Subject reports a quality-of-life rating of 3 or 4 on the Hyperhidrosis Disease Severity Scale (HDSS). * Subject has primary focal axillary hyperhidrosis evidenced by at least 6 months of visible, detectable, focal, exaggerated sweating without any apparent explanation and at least two of the following: * Bilateral and relatively symmetric * Impairs daily activities * Frequency of at least one episode per week * Age of onset less than 25 years old * Positive family history * Cessation of focal sweating during sleep * Subject is willing and able to comply with protocol requirements and all study visits * Willing to have de-identified images of the treated areas taken for possible use in publications and presentations. * Subject understands the study and has provided written informed consent Exclusion Criteria: Subject has secondary hyperhidrosis due to medications, infections, malignancy or endocrinopathy. * Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction and hormonal virilization. * Severe concurrent conditions such as cardiac disorders epilepsy, uncontrolled hypertension, and liver or kidney diseases. * Any active skin condition in the treatment area, such as sores, psoriasis, eczema and rash. * Swollen axillary lymph nodes. * History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin. * Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications. * History of bleeding coagulopathies or use of anticoagulants in the last 10 days. * Prior endoscopic thoracic sympathectomy, liposuction or other surgery for hyperhidrosis in the treated area. Injection of botulinum toxin in the treated area within one year * Use of Isotretinoin (Accutane®) within 6 months prior to study * Oral anticholinergic medication use (e.g., Robinul) or cholinomimetic medication use within the last 4 weeks or planned use during the study's follow up phase. * Currently participating in or recently participated in another clinical trial (within the last 30 days). * History of or current neurologic deficit in the treatment limb. * Known resistance to or history of difficulty with local anesthesia (lidocaine with epinephrine). * Current or history of cancer, including skin cancer, or premalignant moles. * Injury in the treatment area or any other condition that, in the opinion of the investigator, might make treatment unsafe. * Subject has a pacemaker, defibrillator or other electronic implant anywhere in the body. * Permanent implant in the treated area such as metal plates, screws and metal piercing or silicon. * Females who are pregnant or nursing * Female subjects of childbearing potential not willing to use an acceptable form of contraception for the duration of the study.